Laura Esserman, Principal Investigator at The WISDOM Study, shared a post on LinkedIn:
“Great poster by Kelsey Natsuhara about young women and the I-SPY trial.
Even if they had terrible cancers, if they had a great response to treatment, they did great. We saw the worst outcomes for young women who had immune negative tumors, showing us that we really need to concentrate our efforts to finding better treatment strategies for these women, now.
That is the power of the I-SPY neoadjuvant model. We can learn when things are working and figure out how to make them less toxic, or more tolerable. We can also learn where our treatments aren’t being successful and use the power of science and personalized trials to find better solutions and solve the problem.”
Other articles featuring Laura Esserman on OncoDaily.